IDEXX Laboratories, Inc. $IDXX Shares Sold by Korea Investment CORP

Key Points

• Korea Investment CORP cut its stake in IDEXX by 25.3% in Q3, selling 16,049 shares and now holds 47,264 shares (about 0.06%) valued at roughly $30.2 million.
• Insiders sold 45,957 shares worth about $29.9 million over the last quarter (including a $7.34M sale by EVP George Fennell), leaving corporate insiders with 0.98% ownership.
• Analysts have trimmed price targets but the consensus remains a "Moderate Buy" with a collective target of $783.33 (seven Buy ratings and three Hold ratings).

Korea Investment CORP cut its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 25.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 47,264 shares of the company's stock after selling 16,049 shares during the period. Korea Investment CORP owned about 0.06% of IDEXX Laboratories worth $30,196,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of IDXX. Empowered Funds LLC grew its stake in IDEXX Laboratories by 6.6% during the 1st quarter. Empowered Funds LLC now owns 1,538 shares of the company's stock worth $646,000 after buying an additional 95 shares during the last quarter. Sivia Capital Partners LLC purchased a new stake in IDEXX Laboratories in the second quarter valued at approximately $265,000. Moors & Cabot Inc. acquired a new stake in shares of IDEXX Laboratories in the second quarter valued at approximately $228,000. Savant Capital LLC boosted its holdings in shares of IDEXX Laboratories by 88.1% in the second quarter. Savant Capital LLC now owns 3,955 shares of the company's stock valued at $2,121,000 after acquiring an additional 1,852 shares during the period. Finally, Vestmark Advisory Solutions Inc. purchased a new position in shares of IDEXX Laboratories during the second quarter worth approximately $828,000. Institutional investors and hedge funds own 87.84% of the company's stock.

Analysts Set New Price Targets

IDXX has been the topic of a number of recent research reports. Piper Sandler cut their target price on shares of IDEXX Laboratories from $775.00 to $750.00 and set a "neutral" rating on the stock in a report on Monday, February 9th. Wall Street Zen cut shares of IDEXX Laboratories from a "strong-buy" rating to a "buy" rating in a research note on Saturday, February 28th. UBS Group lowered their price objective on shares of IDEXX Laboratories from $750.00 to $730.00 and set a "neutral" rating on the stock in a research report on Tuesday, February 3rd. Barclays reduced their target price on shares of IDEXX Laboratories from $850.00 to $800.00 and set an "overweight" rating for the company in a report on Thursday, February 5th. Finally, BTIG Research decreased their target price on shares of IDEXX Laboratories from $830.00 to $800.00 and set a "buy" rating for the company in a research note on Tuesday, February 3rd. Seven investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat.com, IDEXX Laboratories currently has a consensus rating of "Moderate Buy" and a consensus target price of $783.33.

Insiders Place Their Bets

In other news, Director Sophie V. Vandebroek sold 1,464 shares of IDEXX Laboratories stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $628.62, for a total value of $920,299.68. Following the sale, the director owned 648 shares of the company's stock, valued at $407,345.76. The trade was a 69.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP George Fennell sold 11,345 shares of the business's stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the transaction, the executive vice president owned 9,823 shares in the company, valued at approximately $6,352,730.56. This trade represents a 53.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 45,957 shares of company stock valued at $29,862,109. Corporate insiders own 0.98% of the company's stock.

IDEXX Laboratories Price Performance

IDEXX Laboratories stock opened at $610.45 on Tuesday. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.23 and a quick ratio of 0.90. The business has a 50 day simple moving average of $665.39 and a 200-day simple moving average of $668.46. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $769.98. The stock has a market capitalization of $48.60 billion, a PE ratio of 46.71, a price-to-earnings-growth ratio of 3.69 and a beta of 1.66.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings data on Monday, February 2nd. The company reported $2.92 earnings per share for the quarter, missing analysts' consensus estimates of $2.93 by ($0.01). The firm had revenue of $1.09 billion during the quarter, compared to analysts' expectations of $1.07 billion. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The business's quarterly revenue was up 14.3% on a year-over-year basis. During the same quarter last year, the business earned $2.53 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Equities analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.